Impact of arrhythmia circuit cryoablation during Fontan conversion for refractory atrial tachycardia

1999 ◽  
Vol 83 (4) ◽  
pp. 563-568 ◽  
Author(s):  
Barbara J Deal ◽  
Constantine Mavroudis ◽  
Carl L Backer ◽  
Christopher L Johnsrude ◽  
Albert P Rocchini
2011 ◽  
Vol 3 (1) ◽  
pp. 80
Author(s):  
Alexander Feldman ◽  
Jonathan M Kalman ◽  
◽  

Focal atrial tachycardia (AT) is a relatively uncommon cause of supraventricular tachycardia, but when present is frequently difficult to treat medically. Atrial tachycardias tend to originate from anatomically determined atrial sites. The P-wave morphology on surface electrocardiogram (ECG) together with more sophisticated contemporary mapping techniques facilitates precise localisation and ablation of these ectopic foci. Catheter ablation of focal AT is associated with high long-term success and may be viewed as a primary treatment strategy in symptomatic patients.


2009 ◽  
Vol 150 (36) ◽  
pp. 1694-1700 ◽  
Author(s):  
Attila Mihálcz ◽  
Csaba Földesi ◽  
Attila Kardos ◽  
Károly Ladunga ◽  
Tamás Szili-Török

Pitvarfibrilláció miatt végzett pulmonalis vena izolációját követően a betegek egy részénél iatrogén bal pitvari tachycardia jelentkezik. Cél: A sotalolterápia hatásosságának összehasonlítása az 1C tip. propafenonnal szemben, a postablatiós arrhythmiák kezelésében. Módszer és eredmények: A vizsgálatba 75, pitvarfibrillációban szenvedő beteget (átlagéletkor 55,4 ± 7,14 év) választottunk, akiknél a pulmonalis vénák valódi elektromos izolálását végeztük. A beavatkozás során az elektromos izolációt körkörös multipoláris katéterrel ellenőriztük. Az ablatiót követően folytattuk az antiarrhythmiás terápiát még minimum 6 hétig, de célunk annak leépítése volt. Az utánkövetést 1, majd 3 havonta tervezett, ambuláns vizsgálatok alapján végeztük. A 12. hónap végén 67 betegnél tudtuk a protokoll szerint gyűjtött adatokat elemezni. 21 betegnél jelentkezett 3 hónapot követően tartósan bal pitvari tachycardia (31,3%). 11 beteg propafenon-, 4 beteg amiodaron- és 6 beteg sotalolterápiában részesült. Az első két csoportnál sotalolterápiára váltottunk, míg az utolsó csoportnál propafenonterápiát kezdtünk. A 12. hónap végére a sotalol hatásossága 80%, a propafenon hatásossága 20% volt. Következtetések: Adataink alapján PV-izolációt követően a sotalolterápia nem hatásosabb a bal pitvari tachycardiák megelőzésében, mint a propafenon. A 3 hónapon túl fellépő postablatiós bal pitvari tachycardiák kezelésében a sotalol hatásosabb, mint az IC-csoportba tartozó propafenon.


2021 ◽  
Author(s):  
Wenzhi Shen ◽  
Yu Liu ◽  
Jian Bai ◽  
Zheng Chen ◽  
Xiaohong Li ◽  
...  

2021 ◽  
pp. 1-7
Author(s):  
Tevfik Karagöz ◽  
İlker Ertuğrul ◽  
Ebru Aypar ◽  
Aydın Adıgüzel ◽  
Hayrettin Hakan Aykan ◽  
...  

Abstract Introduction: Accessory pathways are commonly seen due to delamination of tricuspid valve leaflets. In addition to accessory pathways, an enlarged right atrium due to tricuspid regurgitation and incisional scars creates substrates for atrial re-entries and ectopic tachycardia. We sought to describe our experience with catheter ablation in children with Ebstein’s anomaly. Methods and results: During the study period, of 89 patients diagnosed with Ebstein’s anomaly, 26 (30.9%) of them who underwent 33 ablation procedures were included in the study. Accessory pathways were observed in the majority of procedures (n = 27), whereas atrial flutter was observed in five, atrioventricular nodal reentrant tachycardia in five, and atrial tachycardia in two procedures. Accessory pathways were commonly localised in the right posteroseptal (n = 10 patients), right posterolateral (n = 14 patients), septal (n = two patients), and left posteroseptal (n = one patient) areas. Multiple accessory pathways and coexistent arrhythmia were observed in six procedures. All ablation attempts related to the accessory pathways were successful, but recurrence was observed in five (19%) of the ablations. Ablation for atrial flutter was performed in five patients; two of them were ablated successfully. One of the atrial tachycardia cases was ablated successfully. Conclusions: Ablation in patients with Ebstein’s anomaly is challenging, and due to nature of the disease, it is not a rare occasion in this group of patients. Ablation of accessory pathways has high success, but also relatively high recurrence rates, whereas ablation of atrial arrhythmias has lower success rates, especially in operated patients.


2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
P Rujirachun ◽  
P Wattanachayakul ◽  
N Charoenngam ◽  
A Winijkul ◽  
P Ungprasert

Abstract Background and objectives Little is known about atrial involvement in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). Recent studies have suggested that atrial arrhythmia (AA), including atrial fibrillation (AF), atrial flutter (AFL), and atrial tachycardia (AT), was common among these patients although the reported prevalence varied considerably across the studies. Methods We searched for published articles indexed in MEDLINE and EMBASE databases from inception through Sep 22, 2019 to identify cohort studies of patients with ARVC that described the prevalence of atrial arrhythmia among the participants. The pooled prevalence across studies was calculated. Results A total of 16 cohort studies with 1,986 patients with ARVC were included into this meta-analysis. The pooled prevalence of overall AA among patients with ARVC was 17.9% (95% CI, 13.0%–24.0%; I2 88%), the pooled prevalence of AF of 12.9% (95% CI, 9.6%–17.0%; I2 78%), the pooled prevalence of AFL of 5.9% (95% CI, 3.7%–9.2%; I2 70%), and the pooled prevalence of AT of 7.1% (95% CI, 3.7%–13.0%; I2 49%). Conclusions AA is common among patient with ARVC with the pooled prevalence of approximately 18%, which is substantially higher than the reported prevalence of AA in general population. Funding Acknowledgement Type of funding source: None


Sign in / Sign up

Export Citation Format

Share Document